biostudies-literatureUnknown12Galactionova K<h4>Background</h4>Patients with hormone receptor-positive, HER2-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy (NACT) are at a high risk of relapse. PENELOPE-B was a double-blind, placebo-controlled, phase III trial that investigated adding palbociclib (PAL) for thirteen 28-day cycles to adjuvant endocrine therapy (ET) in these patients. Clinical results showed no significant improvement in invasive disease-free survival with PAL.<h4>Methods</h4>We performed a pre-planned cost-effectiveness analysis of PAL within PENELOPE-B from the perspective of the German statutory health insurance. Health-related quality of life scores, collected in the trial using the EQ-5D-3L instrument, were converted to utilities based on the German valuation algorithm. ReFrontiers in oncology886831https://www.ebi.ac.uk/biostudies/studies/S-EPMC9484462biostudies-literatureCost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.PMC9484462McCarthy NMarme FMakris ARugo HSBonnefoi HRToi MSchwenkglenks MKelly CMReimer TGarcia-Saenz JABurchardi NKim SBBear HDGnant MGelmon KALoibl SUntch MMartin MGalactionova KSalari PfalseCost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.<h4>Background</h4>Patients with hormone receptor-positive, HER2-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy (NACT) are at a high risk of relapse. PENELOPE-B was a double-blind, placebo-controlled, phase III trial that investigated adding palbociclib (PAL) for thirteen 28-day cycles to adjuvant endocrine therapy (ET) in these patients. Clinical results showed no significant improvement in invasive disease-free survival with PAL.<h4>Methods</h4>We performed a pre-planned cost-effectiveness analysis of PAL within PENELOPE-B from the perspective of the German statutory health insurance. Health-related quality of life scores, collected in the trial using the EQ-5D-3L instrument, were converted to utilities based on the German valuation algorithm. Re2022-01-01T00:00:00Z20222025-04-18T22:23:59.742Z2024-11-09T20:50:54.882ZS-EPMC94844623613215310.3389/fonc.2022.886831